News
Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers struck a truce after sparring over compounded versions of the pharma giant's branded GLP-1 drugs.
Hosted on MSN2mon
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’If you tuned in to Super Bowl LIX, perhaps you caught the commercial for compounded weight-loss drugs from telehealth company Hims & Hers. The third-quarter ad, called “Sick of the System,” is ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
“If HIMS is able to generate commercial success for liraglutide, it would represent a significant milestone and validate the strength of HIMS’ brand, in our view.” ...
Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales of a significant drug set to fade, commercial innovations are needed to maintain the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback